BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsCommercial

IRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026. Ms. Clase has served as Tarsus’ Interim Chief Commercial Officer since July 2026 and previously

Related news

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-11-03 21:05 EST

Tarsus Reports Third Quarter 2026 Financial Results

OTLKOutlook2026-08-27 20:05 EST

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

OTLKOutlook2026-10-09 12:30 EST

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

BLTEBelite Bio2026-08-24 20:00 EST

Belite Bio to Host Virtual Commercial Day on September 2, 2026

HROWHarrow, Inc.2026-07-01 11:00 EST

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

RHHBYRoche Holdings AG2026-10-28 06:00 EST

Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

LENZLenz Therapeutics Inc2026-07-06 12:15 EST

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

OCSOculis2026-11-02 07:00 EST

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

KPRXKiora Pharmaceuticals2026-09-08 11:00 EST

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-11-05 21:30 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-11-03 21:05 EST

Tarsus Reports Third Quarter 2026 Financial Results

TARSTarsus Pharmaceuticals2026-10-29 20:30 EST

Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

TARSTarsus Pharmaceuticals2026-10-28 12:30 EST

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

TARSTarsus Pharmaceuticals2026-09-29 12:30 EST

Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting

Stock data

Close
67.52 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States